Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer.
Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer.
复制标题
大规模单细胞和批量测序分析揭示了 CD147 在泛癌症中的预后价值和免疫方面
DOI：
10.3389/fimmu.2022.810471
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
CD147在肿瘤微环境中促进肿瘤增殖、抑制癌细胞凋亡发挥重要作用。然而，CD147参与肿瘤发生的机制尚不清楚。本研究系统分析了CD147在31种肿瘤类型中的预后价值和免疫特性。探讨了CD147在泛癌组织中的表达水平和突变格局。应用Kaplan-Meier （KM）分析CD147的预后价值。通过TIMER 2.0和R包（immunedeconv）评估CD147在肿瘤微环境中的免疫特性。我们还通过基因集变异分析和单细胞测序分析探讨了CD147在肿瘤细胞和基质细胞中的表达。采用组织芯片多重免疫荧光染色检测泛癌组织中CD147和巨噬细胞标志物CD68、CD163的共表达。发现CD147在几乎所有癌症类型中都过表达，这与不良预后有关。CD147的表达与肿瘤微环境中的免疫浸润、免疫检查点分子和新抗原水平密切相关。此外，CD147在肿瘤微环境中的多种细胞类型上均有表达，包括肿瘤细胞、巨噬细胞、T细胞、单核细胞、成纤维细胞等。此外，多重免疫荧光显示CD147和巨噬细胞标志物CD68和CD163在许多肿瘤类型中的共表达模式。最后，预测基于CD147表达的免疫治疗反应和敏感小分子药物。综上所述，CD147与多种癌症类型的临床结局和免疫浸润有显著关系。抑制cd147依赖的信号通路可能是一种很有前途的肿瘤免疫治疗策略。
CD147 plays an important role in promoting tumor proliferation and inhibiting cancer cell apoptosis in the tumor microenvironment. However, the mechanisms by which CD147 is involved in tumorigenesis remains unclear. This study systematically analyzed the prognostic value and immune characteristics of CD147 in 31 cancer types. The expression levels and mutant landscapes of CD147 in pan-cancer were explored. The Kaplan-Meier (KM) analysis was applied to analyze the prognostic value of CD147. The immune characteristics of CD147 in the tumor microenvironment were evaluated via TIMER 2.0 and R package (immunedeconv). We also explored the expression of CD147 on tumor cells and stromal cells through Gene Set Variation Analysis and single-cell sequencing analysis. The co-expression of CD147 and macrophage markers CD68 and CD163 in pan-cancer was detected using multiplex immunofluorescence staining on tissue microarrays. CD147 was found to be overexpressed in almost all cancer types, which was related to poor outcome. CD147 expression exhibited a strong association with immune infiltrates, immune checkpoint molecules, and neoantigen levels in the tumor microenvironment. In addition, CD147 was expressed on various cell types in the tumor microenvironment, including tumor cells, macrophages, T cells, monocytes, fibroblasts, etc. Furthermore, multiplex immunofluorescence revealed the co-expression pattern of CD147 and macrophage markers CD68 and CD163 in many tumor types. Finally, the immunotherapy response and sensitive small molecule drugs based on CD147 expression were predicted. In sum, CD147 has a significant relationship with the clinical outcome and immune infiltrates in multiple cancer types. Inhibiting the CD147-dependent signaling pathways might be a promising therapeutic strategy for tumor immunotherapy.